1. Basic Product Identification
Canagliflozin
INN Name: Canagliflozin
Brand Name: Invokana®
Therapeutic Class: Antidiabetic agent
Pharmacological Class: SGLT2 (Sodium-Glucose Co-Transporter-2) inhibitor
Dosage Forms: Oral tablets
Strengths: 100 mg, 300 mg
Primary Indication: Type 2 Diabetes Mellitus (T2DM)
2. Therapeutic Knowledge
Canagliflozin is used for:
Type 2 diabetes mellitus (glycemic control)
Reduction of cardiovascular risk (in selected patients)
Diabetic kidney disease (renal protection benefits)
Weight reduction (secondary benefit)
Blood pressure reduction (mild diuretic effect)
???? Key clinical advantage:
Works independent of insulin secretion
3. Mechanism of Action (MOA)
Canagliflozin inhibits:
SGLT2 transporters in proximal renal tubules
Normal physiology:
Glucose reabsorbed in kidney via SGLT2
Drug action:
Blocks glucose reabsorption
Increases urinary glucose excretion (glucosuria)
???? Result:
↓ Blood glucose
↓ Body weight
↓ Blood pressure (osmotic diuresis)
4. Pharmacokinetics (ADME)
Absorption: Moderate oral absorption
Tmax: ~1–2 hours
Bioavailability: ~65%
Protein binding: ~99%
Metabolism: UGT1A9 and UGT2B4 (glucuronidation)
Half-life: ~10–13 hours
Excretion: Feces (~60%), urine (~33%)
⚠️ Minimal CYP involvement → fewer drug interactions
5. Dosage & Administration
Starting dose: 100 mg once daily (before first meal)
Maintenance dose: 300 mg once daily (if tolerated)
Dose adjustment:
Renal impairment limits use
Elderly caution required
Monitoring:
Renal function (eGFR)
Blood glucose
Electrolytes
6. Formulation Knowledge
Immediate-release oral tablets
Film-coated dosage form
Excipients:
Microcrystalline cellulose
Lactose monohydrate
Croscarmellose sodium
Magnesium stearate
Film coating polymers (HPMC, PEG)
Formulation challenges:
Moisture stability
Uniform drug distribution at low doses
Taste masking not required (tablet form)
7. Raw Materials Knowledge
API: Canagliflozin hemihydrate
Chemical class:
C-glucoside SGLT2 inhibitor
Key intermediates:
Aromatic glycoside precursors
Fluorinated benzyl intermediates
Critical raw material risks:
Stereochemical purity (C-glycoside linkage stability)
Polymorph control (hemihydrate form stability)
8. Manufacturing Process Knowledge
API synthesis involves:
C–C glycosidic bond formation (key step)
Fluorinated aromatic coupling reactions
Protection/deprotection chemistry
Crystallization to hemihydrate form
Tablet manufacturing:
Wet granulation or direct compression
Blending uniformity critical
Low-dose homogeneity validation
9. Analytical & QC Knowledge
Key QC tests:
HPLC assay (potency)
Related substances / impurity profiling
Dissolution testing (USP/Ph.Eur)
Water content (Karl Fischer for hemihydrate control)
Polymorph identification (XRPD)
Content uniformity
Residual solvents (GC)
Critical quality attributes:
Polymorph stability (hemihydrate form)
Dissolution consistency
10. Regulatory Knowledge
Approved by:
FDA (US)
EMA (EU)
CDSCO (India)
Indication expansion:
Cardiovascular and renal protection claims (region-specific)
Regulatory focus:
Amputation risk warning (historical FDA alert)
Renal function labeling updates
Requires:
Cardiovascular outcome trials (CVOT data)
11. Storage & Stability
Store at 20–25°C
Protect from:
Moisture (important for hemihydrate stability)
Stable crystalline form required for bioavailability consistency
Stability risks:
Polymorphic conversion
Humidity-induced degradation
12. Packaging Knowledge
Alu-Alu blister packs (moisture barrier)
HDPE bottles with desiccant
Child-resistant closures
Secondary packaging:
Diabetes medication labeling
Kidney function warning labels
13. Safety & Toxicology
Major risks:
Genital fungal infections
Urinary tract infections
Volume depletion (dehydration)
Ketoacidosis (rare but serious)
Lower limb amputation risk (historical concern, now risk-mitigated)
Contraindications:
Severe renal impairment (low eGFR)
Monitoring:
Kidney function (eGFR)
Hydration status
Ketone levels in high-risk patients
14. Market & Commercial Knowledge
Competes with:
Empagliflozin
Dapagliflozin
Ertugliflozin
Advantages:
Strong glycemic + weight loss effect
Limitations:
Safety warnings (amputation risk history)
Market segment:
Massive Austria global diabetes market (SGLT2 class fast-growing)
15. Intellectual Property (IP)
Originator: Janssen Pharmaceuticals (J&J)
Patent status:
Primary patents expired/expiring in multiple regions
Generic availability:
Increasing globally
IP focus areas:
Combination therapies (metformin + canagliflozin)
Fixed-dose combinations
16. Environmental & EHS Knowledge
API manufacturing:
Fluorinated intermediates require controlled handling
Waste:
Organic solvent recovery mandatory
Worker safety:
PPE required for fluorinated compound handling
Environmental concern:
Persistent fluorinated residues in waste streams
17. Export Documentation Knowledge
Required documents:
DMF / ASMF
COA (API & finished product)
GMP certificate
Stability data (ICH Q1A)
Bioequivalence study reports
Impurity profiling report
MSDS
Batch manufacturing records
18. Business Development Knowledge
Target markets:
Diabetes specialty chains
Endocrinology clinics
Government diabetes programs
Strategy:
Position as cardio-renal-metabolic drug
Growth drivers:
Rising diabetes + CKD prevalence globally
Competitive strategy:
Fixed-dose combinations (metformin + SGLT2 inhibitors)
19. Advanced Technical Knowledge
C-glucoside structure → high metabolic stability vs O-glucosides
SGLT2 inhibition → insulin-independent glucose excretion
Osmotic diuresis → secondary BP reduction
Cardiovascular benefit linked to:
Hemodynamic changes
Reduced intraglomerular pressure
20. AI & Digital Knowledge (Modern Pharma)
Applications:
AI-driven prediction of renal response (eGFR decline modeling)
Diabetes progression forecasting
Digital twin modeling for SGLT2 response
Pharmacovigilance detection of ketoacidosis signals
Smart adherence monitoring via glucose data integration
21. Sales Team Product Knowledge Checklist
Sales must know:
SGLT2 inhibitor class
Works independent of insulin
Indicated for type 2 diabetes
Weight loss + BP reduction benefits
Kidney function monitoring required
Infection risk (UTI/genital infections)
Hydration counseling essential
Not for type 1 diabetes (risk of ketoacidosis)
22. Most Important Technical Documents
DMF / ASMF
Stability studies (ICH Q1A)
Polymorph characterization (XRPD)
Bioequivalence study report
Dissolution profile data
Impurity profiling report
CVOT clinical data summary
Manufacturing validation batch records
23. Ultimate Pharma Product Mastery Summary
Canagliflozin is:
A SGLT2 inhibitor oral antidiabetic agent
Provides insulin-independent glucose lowering
Offers cardio-renal metabolic benefits
A key molecule in modern diabetes + kidney disease therapy
???? Strategic importance:
Core drug in global diabetes markets
Strong cardio-renal protection positioning
High generic competition but sustained demand
Essential part of modern metabolic therapy portfolios